VedaBio Demonstrates Sub-10-Minute Molecular Detection with CRISPR Technology
VedaBio, a biotechnology company, has announced new proof-of-concept data demonstrating molecular detection in under 10 minutes using its integrated, target amplification-free CRISPR-based technology. These findings were presented at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle, Washington. The technology aims to overcome challenges in bringing molecular testing closer to patients by reducing the time and complexity associated with conventional methods. In a proof-of-concept study, VedaBio's integrated prototype achieved rapid, multiplex molecular detection for a five-result respiratory panel, including automated nucleic acid extraction. Brett Robb, PhD, Chief Scientific Officer of VedaBio, emphasized that the goal is to challenge the limitations of speed, complexity, and performance in molecular diagnostics, making it more accessible for urgent care and other decentralized settings.